Search International and National Patent Collections
Refine Search
Query Tree
Save query
A private query is only visible to you when you are logged-in and can not be used in RSS feeds
Results 1-10 of 1,551 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 156
Analysis
List Length
TitleCtrPubDate
Appl.NoApplicantInventorInt.Class
Kutkin derivative, preparation method and application thereof
CN07.03.2007
200610037302.1Jinan UniversityJiang Jie
C07C 69/035
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
C
ACYCLIC OR CARBOCYCLIC COMPOUNDS
69
Esters of carboxylic acids; Esters of carbonic or haloformic acids
02
Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
035
esterified with a hydroxy compound having the esterified hydroxy group bound to a carbon atom of a six-membered aromatic ring
The invention discloses a derivant of kutkin with chemical structural formula as formula I, wherein R1 is NO2, NH2 or amide; R2 is H, carbonyl or diaminocarbonyl. The preparing method comprises the following steps: nitrating kutkin to obtain kutkin derivant substituted by nitro group or kutkin derivant based on substituted nitro group; or kutkin derivant substituted by acetylamino.

Process for the production of anhydrosugar alcohols
US13.09.2007
11716277Archer-Daniels-Midland CompanySanborn Alexandra J.
C07D 307/00
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
307
Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom

A process is provided for the preparation of anhydrosugar alcohols. The process involves heating a sugar alcohol or a monoanhydrosugar alcohol starting material in the presence of an acid catalyst and under pressure. Optionally the resulting product is purified. Very high purities are achieved, without necessitating the use of organic solvents in the process.


γ−カルボキシル化タンパク質の製造方法
JP12.04.2007
2006535301アストラゼネカ アクチボラグフェンジ,クリステル
C12N 1/19
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
1
Micro-organisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving micro-organisms or compositions thereof; Processes of preparing or isolating a composition containing a micro-organism; Culture media therefor
14
Fungi; Culture media therefor
16
Yeasts; Culture media therefor
19
modified by introduction of foreign genetic material

本発明は、大量のγ−カルボキシル化されたタンパク質の製造のための方法およびツールであって、(i)γ−カルボキシル化を必要とするタンパク質およびγ−グルタミルカルボキシラーゼを少なくとも10:1の比で発現するように適合させた細胞を両方のタンパク質が発現するのに適した条件下で培養すること、および(ii)γ−カルボキシル化されたタンパク質を単離すること、を含む前記方法およびツールに関する。


Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs
US22.11.2007
11574169Sylentis S.A.U.Jiménez Ana I.
A61K 48/00
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Sequences and protocols for treatment of eye conditions by use of RNA interference are disclosed. Target genes are selected from those responsible for aqueous flow or aqueous outflow, while particularly preferred conditions to be treated include glaucoma and uveitis.


A LIPIDIC EXTRACT FROM LEPIDIUM MEYNII AND ITS EFFECT ON THE LIBIDO
US24.05.2007
11460142NATUREXZheng Qun Yi
A61K 36/185
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36
Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18
Magnoliophyta (angiosperms)
185
Magnoliopsida (dicotyledons)

The present invention relates to compositions containing particular components that can be obtained from a plant which can have pharmaceutical applications. More particularly, the plant genus is Lepidium and the composition may contain in the range of between about 0.3% and 0.7% of benzyl isothiocyanate, b) between about 0.06% and about 0.02% of Lepidium sterol component, c) between about 1% and about 2% of a Lepidium fatty acid component, and d) about 0.006% to 0.6% or more total macamide/macaenes component as standardized with excipients.


Hydroxypropyl Amides for the Treatment of Alzheimer's Disease
US27.09.2007
10575824ELAN PHARMACEUTICALS, INC.Tucker John
A61K 31/165
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
16
Amides, e.g. hydroxamic acids
165
having aromatic rings, e.g. colchicine, atenolol, progabide

The present invention relates to compounds of formula (I) useful in treating Alzheimer's disease and other similar diseases. These compounds include inhibitors of the beta-secretase enzyme that are useful in the treatment of Alzheimer's disease and other diseases characterized by deposition of A beta peptide in a mammal. The compounds of the invention are useful in pharmaceutical compositions and methods of treatment to reduce A beta peptide formation. embedded image


CATIONIC PEPTIDES FOR siRNA INTRACELLULAR DELIVERY
US29.11.2007
11676221NASTECH PHARMACEUTICAL COMPANY INC.Chen Lishan
A61K 31/7042
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31
Medicinal preparations containing organic active ingredients
70
Carbohydrates; Sugars; Derivatives thereof
7042
Compounds having saccharide radicals and heterocyclic rings

What is described is a composition for delivery of a RNA molecule to a cell, comprising: a double stranded RNA (dsRNA) molecule of about 15 to about 40 base pairs; and a polynucleotide delivery-enhancing peptide, comprising a region of alternating lysine and histidine residues, or of alternating D and L forms of arginine.


IL-21 peptides and nucleic acids
EP09.05.2007
06122242NOVO NORDISK ASROEMER JOHN
A61K 38/20
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
19
Cytokines; Lymphokines; Interferons
20
Interleukins
The invention relates to an IL-21 polypeptide having the sequence of residues 30-162 of IL-21 and nucleic acid encoding such polypeptides. Also disclosed is the formulation of pharmaceutical compositions comprising an IL-21 polypeptide and the treatment of conditions where eosinophils are involved in a protective response, e.g. allergic reactions, allergic diseases and parasitical diseases.

Method of treating bone or prostate cancer with selective bradykinin B1 receptor antagonists
US18.01.2007
11451142Societe de Commercialisation des Produits de la Recherche Applique Socpra Sciences Sante et Humaines S.E.C.Nantel François
A61K 38/10
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
04
Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
10
Peptides having 12 to 20 amino acids

Provided is a method for the use of a bradykinin B1 receptor antagonist of formula I: X-CO-Aaa0-Aaa1-Aaa2-Aaa3-Gly-α(Me)Phe-Ser-D-βNal-Aaa8-OH (I) or a pharmaceutically acceptable salt or hydrate thereof wherein: X is CnH2n+1 or CiH2i—C6H5, where n is an integer from 1 to 3, and i is an integer from 0 to 3; Aaa0 is Lys, Orn or Cit; Aaa1 is Arg or Cit, and preferably Arg; Aaa2 is Oic, Hyp or Pro, and preferably Oic; Aaa3 is Pro or Oic, and preferably Pro; and Aaa8 is Ile, Leu or Nle, and preferably Ile, for the treatment of metastases, cancers and/or chemotherapy-induced neuropathies, comprising the administration of the compound to a patient in need of such treatment. Also provided are compositions containing such antagonists and their thereof.


Method for preparing dianhydrohexitol diester compositions
EP12.12.2007
06726130ROQUETTE FRERESFUERTES PATRICK
C07D 493/04
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
D
HETEROCYCLIC COMPOUNDS
493
Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
02
in which the condensed system contains two hetero rings
04
Ortho-condensed systems
The invention concerns a method for preparing a dianhydrohexitol diester composition, characterized in that it comprises a step which consists in esterifying a dianhydrohexitol composition with a carboxylic acid in the presence of an acid catalyst and hypophosphorous acid. Preferably, the hypophosphorous acid is introduced in an amount ranging between 0.05 and 2 wt. % of dianhydrohexitol, and in a hypophosphorous acid/acid catalyst weight ratio less than 1/1. Said method enables novel dianhydrohexitol diester compositions, for example isosorbide diesters, isomannide and/or isoidide richer in diester(s) and/or less coloured, useful in numerous industrial applications, in particular in plastic compositions, to be obtained.

Results 1-10 of 1,551 for Criteria:CHEM:(FBPFZTCFMRRESA-UHFFFAOYSA-N) Office(s):all Language:en Stemming: false
Filters
1 2 3 4 5 6 7 8 9 10 11 12
Page: / 156